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We isolated human brain natriuretic peptide (human BNP) from the human atrium. Sequence analysis has revealed that it is a 32-amino-acid peptide 
with the sequence S-P-K-M-V-Q-G-S-G-C-F-G-R-K-M-D-R-I-S-S-S~S-G-L-G-C-K-V-L-R-R-H, which is identical to the C-terminal sequence 
(77-108) of the human BNP precursor deduced from the cDNA sequence. The sequence of human BNP (77-108) is preceded by Pro75-Arg76 in
the human BNP precursor, which is the same processing signal as Pro9’-ArgB of the precursor of atria1 natriuretic peptide (ANP). The processing 
of the BNP precursor occurs in the cardiocyte, although that of the ANP precursor in the cardiocyte is unclear at present. 
Natriuretic peptide, brain; Natriuretic peptide, atrial; Processing; (Human atrium) 
1. INTRODUCTION 
Since the discovery of porcine brain natriuretic pep- 
tide (BNP), accumulating evidence indicates that a fam- 
ily of natriuretic peptides are involved in the regulation 
of water-electrolyte balance and blood pressure [11. Al- 
though specific radioimmunoassays (RIAs) for porcine 
BNP were established, no porcine BNP-like immunore- 
activity (-LI) has been detected in the heart or in the 
brain of rats, humans, or monkeys [2]. These results in- 
dicate that, unlike atria1 natriuretic peptide (ANP), 
BNP is heterogeneous in the amino acid sequence a- 
mong species. 
Recently, we have isolated rat BNP from rat atria1 tis- 
sues using an antiserum against he ring structure of iso- 
ANP [3,4] and demonstrated that the amino acid se- 
quence of rat BNP is composed of 45 amino acid resi- 
dues [4,5]. Flynn et al. [6] also reported the isolation of 
iso-ANP from the rat atrium but the sequence of iso- 
ANP reported differs from that of rat BNP we reported 
[4,5]. In the course of the isolation of rat BNP, Matsuo 
and his colleagues reported the cDNA sequences encod- 
ing the precursors for human BNP [7] and rat BNP [8]. 
The C-terminal 45amino-acid sequence of the rat BNP 
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precursor is identical with the sequence of rat BNP 
]4,51. 
As for human BNP, we have established a specific 
RIA for human BNP using synthetic human BNP-26 or 
human BNP(83-108) based on the nucleotide sequence 
of the human BNP precursor [7] and demonstrated that 
the major form of human BNP in the atrium is a low- 
molecular-weight form of BNP comigrating with hu- 
man BNP-32 in reverse-phase high performance liquid 
chromatography (RP-HPLC) (Mukoyama et al., un- 
published observations). 
In the present study we have isolated human BNP 
from the human atrium using a specific RIA for human 
BNP and determined its sequence. 
2. MATERIALS AND METHODS 
2.1. Materials 
Human BNP(77-108), or human BNP-32 was synthesized by the 
solid-phase method. a-Human ANP, or ANP(99-126) was synthesiz- 
ed by the conventional solution methods [9]. The atria1 tissue was ob- 
tained at autopsy from a patient without cardiac complications. 
2.2. RIA 
RIA for human BNP used in the present study is reported else- 
where. The cross-reactivity of m-human ANP in the RIA for human 
BNP was less than 0.01% on a molar basis. RIA for ANP was per- 
formed according to the previous report [lo]. The cross-reactivity of 
human BNP-32 in the RIA for ANP was less.than O.Olcrlo. 
2.3. Isolation 
The atrium (50 g) was boiled in 1 M acetic acid (500 ml) for 10 min. 
It was homogenized with a Polytron homogenizer for 10 min and cen- 
trifuged at 15000 rpm for 60 min at 4°C and the supernatant was 
then loaded on an SP-Sephadex C-25 column (Pharmacia, Sweden; 
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50 mm i.d. x 100 mm). After being washed with 1 M acetic acid, the 
adsorbed material was eluted with 2 M pyridine @P-II) and 2 M 
pyridine-acetate (PH 5) (SP-III) successively. The SP-III fraction was 
directly treated with Sep-Pak Cl8 cartridges (Waters, USA). The frac- 
tion passing through the cartridges was diluted twice with 0.1% tri- 
fluoroacetic acid (TFA) and was applied again on other Sep-Pak C18 
cartridges. The eluate with 60% acetonitrile containing 0.1% TFA 
was lyophilized. The resulting material was applied on a Sephadex 
G-50 column (Pharmacia, Sweden; 24 mm i.d. x 410 mm, 1 M acetic 
acid). Two-ml fractions were collected and aliquots were subjected to 
RIA for human BNP. Immunoreactive fractions (nos. 43-50) were 
concentrated with a Sep-Pak Cl8 cartridge. The adsorbed material 
was then applied on a TSK-gel CM-2SW column (Toy0 Soda, Japan; 
4 mm i.d. x 250 mm) and eluted with 10% acetonitrile-0.05% Triton 
X-lOO-ammonium formate (pH 7.4) in a linear gradient from 10 mM 
to 1 .O M. Immunoreactive fractions were purified on a Nucleosil 5Cis 
column (4.6 mm i.d. x 150 mm; Nagel) with a linear gradient of 
acetonitrile from 15-30% in 0.1% TFA. Further purification was per- 
formed by use of a Vydac diphenyl column (4.6 mm i.d. x 250 mm; 
Vydac) as described previously [4]. 
2.4. Lysyl-endopeptidase digestion 
One gg of the isolated peptide was subjected to reductive carboxy- 
methylation and subsequent lysyl endopeptidase digestion according 
to the procedure described previously [4]. The digest was applied on 
a Nucleosil 5Cls column (4.6 mm id. x 150 mm). Four fragments, 
designated Ll, L2, L3 and L4 (fig.4), were separated by gradient elu- 
tion with acetonitrile from 0 to 50% in 0.1% TFA. 
2.5. Sequence analysis 
Three hundred ng of the isolated peptide and the peptide frag- 
ments, Ll, L2, L3 and L4 were subjected to sequence analysis. It was 
carried out by stepwise Edman degradation using a gas-phase se- 
quencer equipped with a RP-HPLC system, Model 477A/120A (Ap- 
plied Biosystems Inc.). 
2.6. Amino acid analysis 
Isolated peptide (100 ng) was hydrolyzed with 6 M HCl at 100°C 
for 24 h. The resulting amino acids were converted to phenylthiocar- 
bamyl derivatives and then analyzed on RP-HPLC according to Ebert 
[l l] with some modifications. 
3. RESULTS 
3.1. Identification of human BNP in HPLC 
The tissue concentrations of human BNP and ANP 
in the human atrium were estimated to be 0.39 pg/g and 
7.85 pg/g, respectively. Fig. 1 shows the elution profiles 
of BNP-LI and ANP-LI of the crude extract of RP- 
HPLC. The major peak with human BNP-LI emerged 
at 22 min, which was the same retention time as that of 
synthetic human BNP-32. On the other hand, ANP-LI 
eluted at the same elution position as that of the ANP 
precursor, y-human ANP . 
3.2. Isolation of human BNP 
On chromatography using SP-Sephadex C-25, about 
10 pg of BNP-LI was detected in the SP-III fraction. In 
gel-permeation chromatography using Sephadex G-50 
(superfine) of the SP-III fraction, BNP-LI appeared in 
the low-molecular-weight region (fig.2). Further purifi- 
cation on HPLC using TSK-gel CM-2SW (carboxy- 
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Fig.1. Elution profile of atria1 extract in RP-HPLC. A Nucleosil5Cis 
column (4.6 mm i.d. x 150 mm) was used. Elution was performed 
with a linear gradient (l%/min) of acetonitrile from 10% to 60% in 
0.1% TFA. ANP-LI and BNP-LI are expressed with a-human ANP 
and human BNP-32 used as standards, respectively. A-C indicate the 
elution positions of synthetic human BNP-32, a-human ANP and its 
dimer , respectively. 
methylated silica gel; a cation exchanger) and Nucleosil 
5Crs (octadecyl silica gel) afforded 4pg of BNP-LI. 
The purified peptide was obtained by HPLC with a 
Vydac diphenyl column (fig.3). The final yield was esti- 
mated to be 1.5 pg of BNP-LI (8%). 
3.3. Sequence determination of human BNP 
The amino acid composition of the isolated peptide is 
shown in table 1. Sequence analysis of the isolated pep- 
tide revealed that the N-terminal sequence is S-P-K-M- 
V-Q-G-S-G-X-F-G-R-K-M-D-R-I-S-S-X-X-G-L-X-X- 
X-V-L-R, where X expresses an unidentified residue. In 
order to elucidate the complete sequence, the intact 
peptide was exposed to reductive carboxymethylation 
and to subsequent enzymatic digestion with lysyl endo- 
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Fig.2. Gel-permeation chromatography of SP-III fraction, Vo, 3K 
and 1K indicate elution positions of bovine thyroglobulin, a-human 
ANP and caerulein, respectively. 
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Fig.3. RP-HPLC of semi-purified immunoreactive material. A Vydac dipheoyl column was used. Elution was performed as described in section 2. 
peptidase. As shown in fig.4, four fragments designated 
Ll, L2, L3 and L4 were obtained. These fragments 
proved to be S-P-K, V-L-R-R-H, M-V-Q-G-S-G-C-F- 
G-R-K and M-D-R-I-S-S-S-S-G-L-G-C-K, respectively, 
by sequence analysis of the individual peptide frag- 
ments. These results on amino acid analysis and se- 
quence analysis indicate that human BNP isolated from 
the human atrium is S-P-K-M-V-Q-G-S-G-C-F-G-R-K- 
M-D-R-I-S-S-S-S-G-L-G-C-K-V-L-R-R-H or human 
BNP(77-108) as illustrated in fig.5. 
Table 1 
Amino acid ratio of the isolated peptide 
Amino acid Ratio Deduced ratioa 
Asx 0.9 1 
Glx 0.7 1 
Ser 5.7 6 
C]Y 5.5 5 
His 0.9 1 
Arg 4.0 4 
Pro 0.9 1 
Val 2.0 2 
Ile 1.0 1 
Leu 2.0 2 
Phe 1.1 1 
LYS 3.0 3 
Met 0.9b 2 
(CYS]Z n.d.’ 1 
a Calculated from the cDNA data [7]. 
b Methionine was recovered as its sulfoxide because hydrolysis was 
carried out under usual conditions as described in section 2. The low 
recovery may be due to degradation on acid hydrolysis. 
’ Not determined. 
4. DISCUSSION 
In the present study, we have isolated human BNP 
from the human atrium and demonstrated that human 
BNP is a 32-amino-acid peptide, which corresponds to 
the C-terminal sequence (77-108) of the human BNP 
precursor deduced from the cDNA sequence [7]. The 
sequence of human BNP(77-108), or human BNP-32 is 
preceded by Pro7’-Arg76 in the human BNP precursor 
[7], which is the same processing signal as that of the 
ANP precursor [ 121. The accumulated evidence in- 
dicates that ANP is stored as its precursor or y-ANP 
(ANP( l-126)) in the heart and that it is secreted from 
the heart as a-ANP or ANP(99-126), which is generat- 
ed by the processing at the Pro97-Arg98 sequence of y- 
ANP on secretion [13,141. In contrast, the present study 
clearly shows that the major storage form of BNP in the 
human atrium is not the human BNP precursor but hu- 
man BNP-32, suggesting that the processing of the BNP 
precursor at the signal of Pro75-Arg76 occurs in the hu- 
man atrium. Further studies are necessary to elucidate 
the mechanism of the preferential processing of the 
BNP precursor in the human heart. 
Porcine BNP is stored as a large molecule, 
BNP(l-106), in the heart [15,16] and is present as 
BNP-26 and BNP-32 in the brain [ 1,171. Rat BNP in the 
rat heart exists mainly as a 45amino-acid peptide, 
which is secreted into the circulation [3-51. In addition, 
bovine BNP, or ASIF (aldosterone secretion inhibitory 
factor) which was isolated from bovine chromaffin cells 
is known to be a 35-amino-acid peptide, of which C- 
terminal 28-amino-acid sequence is identical with that 
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Fig.4. RP-HPLC of lysyl-endopeptidase digests of carboxymethylated human BNP. 
--___----- _-+_4- 
Ser-Pro-Lys-net-V~l~llo~ly-Ser~ly-Cye-Phe~ly-ArS-Ly~-~et-~p- 
I cLl-+-L3-+--- 
4_4- __ _+_ 
~Ig-lle-Ser-Sec-Ser-Ser~ly-~u~ly-cys-Ly~-v~l-~u-~g-ArS-~i~ 
~------l-=--l 
Fig.5. Amino acid sequence of human BNP. Arrows indicate the resi- 
dues determined by sequence analysis of the native peptide. 
of porcine BNP-32 [ 181. These previous observations 
and the finding on human BNP in the present study in- 
dicate that the molecular form of BNP varies markedly 
among species unlike ANP. 
Recently, two types of human receptors for 
natriuretic peptides, ANP-A and ANP-B receptors, 
possessing the guanylate cyclase domain were deter- 
mined by molecular cloning [ 19-211. In these studies, it 
was reported that the ANP-B receptor is preferentially 
activated by porcine BNP rather than a-human ANP, 
whereas the ANP-A receptor responds similarly to both 
natriuretic peptides. Therefore, the sequence determi- 
nation of human BNP achieved in the present study 
opens up the new research field in the signal transduc- 
tion system of natriuretic peptides, ANP and BNP, in 
humans. 
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